- Home
- FMAO vs ABEO Comparison
FMAO vs ABEO Comparison
Compare FMAO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- ABEO
- Stock Information
- Founded
- FMAO 1897
- ABEO 1974
- Country
- FMAO United States
- ABEO United States
- Employees
- FMAO N/A
- ABEO N/A
- Industry
- FMAO Savings Institutions
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- ABEO Health Care
- Exchange
- FMAO Nasdaq
- ABEO Nasdaq
- Market Cap
- FMAO 358.1M
- ABEO 289.2M
- IPO Year
- FMAO N/A
- ABEO 1980
- Fundamental
- Price
- FMAO $23.68
- ABEO $5.38
- Analyst Decision
- FMAO
- ABEO Strong Buy
- Analyst Count
- FMAO 0
- ABEO 6
- Target Price
- FMAO N/A
- ABEO $18.17
- AVG Volume (30 Days)
- FMAO 20.6K
- ABEO 980.7K
- Earning Date
- FMAO 10-28-2025
- ABEO 11-13-2025
- Dividend Yield
- FMAO 3.83%
- ABEO N/A
- EPS Growth
- FMAO 38.39
- ABEO N/A
- EPS
- FMAO 2.16
- ABEO 0.99
- Revenue
- FMAO $108,632,000.00
- ABEO $400,000.00
- Revenue This Year
- FMAO $3.38
- ABEO N/A
- Revenue Next Year
- FMAO $6.39
- ABEO $324.71
- P/E Ratio
- FMAO $10.71
- ABEO $5.44
- Revenue Growth
- FMAO 13.86
- ABEO N/A
- 52 Week Low
- FMAO $20.88
- ABEO $3.93
- 52 Week High
- FMAO $34.15
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- FMAO 41.51
- ABEO 43.21
- Support Level
- FMAO $22.89
- ABEO $5.21
- Resistance Level
- FMAO $25.06
- ABEO $5.70
- Average True Range (ATR)
- FMAO 0.92
- ABEO 0.24
- MACD
- FMAO -0.16
- ABEO 0.05
- Stochastic Oscillator
- FMAO 31.16
- ABEO 44.04
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.